FAOD In Focus for HCP

Energy in the Balance

Long-chain fatty acid oxidation disorders (LC-FAOD) are characterized by an unbalanced metabolism that impairs energy production.1,2

LC-FAOD are a group of rare, often severe, and life-threatening autosomal recessive disorders that result from defective enzymes involved in the transport and catabolism of long-chain fatty acids (LCFAs).1-4
LC-FAOD include the following types4:

Carnitine palmitoyltransferase I (CPT I) deficiency

CPT I deficiency is caused by mutations in the CPT1A gene encoding CPT IA, a liver isoform, preventing LCFAs from entering mitochondria for fatty acid β-oxidation. Key symptoms (birth to 18 months) are related to liver function and include hepatic encephalopathy, hypoketotic hypoglycemia, seizures, and sudden unexpected death in infancy; muscle and heart symptoms are absent.1,5,6

Carnitine-acylcarnitine translocase (CACT) deficiency

CACT deficiency is caused by mutations in the SLC25A20 gene encoding CACT, leading to disruption of LCFAs mitochondrial import for β-oxidation. Symptoms include hypoketotic hypoglycemia, respiratory distress, seizures, hypotonia, bradycardia/other arrhythmias, cardiac failure, and hyperammonemia; often fatal at birth or early infancy.7,8

Carnitine palmitoyltransferase II (CPT II) deficiency

CPT II deficiency is caused by mutations in the CPT2 gene encoding CPT II, preventing LCFAs from being transported into mitochondria for fatty acid β-oxidation. Key symptoms include hypoketotic hypoglycemia (childhood), cardiomyopathy, and muscular symptoms (adolescence/adulthood).7,9

Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency

VLCAD deficiency is caused by mutations in the ACADVL gene encoding VLCAD and is the most common form of LC-FAOD. VLCAD catalyzes the initial rate-limiting step in mitochondrial fatty acid β-oxidation. VLCAD deficiency is clinically heterogenous, with three major phenotypes: a severe early childhood onset form with high rates of both cardiomyopathy and mortality; a milder, later childhood onset form that mainly presents with hypoketotic hypoglycemia and has low rates of mortality and cardiomyopathy; and an adult form with isolated skeletal muscle involvement, rhabdomyolysis, and myoglobinuria that are usually triggered by exercise or fasting.3,7,10

Trifunctional protein (TFP) deficiency

TFP deficiency is heterogeneous, with mutations identified in both the HADHA and HADHB genes, leading to defects in the 3 enzymes that comprise the TFP complex. Key symptoms include hypoketotic hypoglycemia (childhood), cardiomyopathy, muscular symptoms, peripheral neuropathy (more often generalized TFP), and pigmentary retinopathy (more often isolated long-chain 3-hydroxyacyl-CoA dehydrogenase, or LCHAD, deficiency).11-13

Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency

LCHAD deficiency is caused by mutations in the HADHA gene encoding the α subunit of trifunctional protein (TFP). It prevents the breakdown of 3-hydroxyacyl-CoA to 3-ketoacyl-CoA, causing an accumulation of acylcarnitines and other fatty acids. Key symptoms include hypoketotic hypoglycemia (childhood), cardiomyopathy, muscular symptoms, peripheral neuropathy (more often generalized TFP), and pigmentary retinopathy (more often isolated LCHAD).1,11-16

Patients with LC-FAOD face difficult challenges and substantial medical burdens

When energy balance is disrupted, chronic symptoms and acute episodes burden patients1,17-20

When LC-FAOD is Suspected

Confirmatory genetic testing may be appropriate for anyone with a suspected LC-FAOD diagnosis1

Up-to-date information on LC-FAOD

Explore selected publications and resources that provide valuable insights and support for patients and caregivers

References

1. Knottnerus SJG, Bleeker JC, Wüst RCI, et al. Rev Endocr Metab Disord. 2018;19(1):93-106. 2. Wajner M, Amaral AU. Biosci Rep. 2015;36(1):e00281. 3. Lindner M, Hoffmann GF, Matern D. J Inherit Metab Dis. 2010;33(5):521-526. 4. Wanders RJ, Ruiter JP, IJLst L, Waterham HR, Houten SM. J Inherit Metab Dis. 2010;33(5):479-494. 5. Bennett MJ, Santani AB. Carnitine Palmitoyltransferase 1A Deficiency. July 27, 2005 [Updated March 17, 2016]. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020. 6. Ogawa E, Kanazawa M, Yamamoto S, et al. J Hum Genet. 2002;47(7):342-347. 7. Pennisi EM, Garibaldi M, Antonini G. J Clin Med. 2018;7(12):E472. 8. Vitoria I, Martín-Hernández E, Peña-Quintana L, et al. JIMD Rep. 2015;20:11-20. 9. Wieser T. Carnitine Palmitoyltransferase II Deficiency. August 27, 2004 [Updated January 3, 2019]. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020. 10. Andresen BS, Olpin S, Poorthuis BJ, et al. Am J Hum Genet. 1999;64(2):479-494. 11. De Biase I, Viau KS, Liu A, et al. JIMD Rep. 2017;31:63-71. 12. Rinaldo P, Matern D, Bennett MJ. Annu Rev Physiol. 2002;64:477-502. 13. Ibdah JA, Bennett MJ, Rinaldo P, et al. N Engl J Med. 1999;340(22):1723-1731. 14. den Boer ME, Wanders RJ, Morris AA, IJlst L, Heymans HS, Wijburg FA. Pediatrics. 2002;109(1):99-104. 15. Raval DB, Cusmano-Ozog KP, Ayyub O, et al. Mol Genet Metab Rep. 2016;10:8-10. 16. Fletcher AL, Pennesi ME, Harding CO, Weleber RG, Gillingham MB. Mol Genet Metab. 2012;106(1):18-24. 17. Saudubray JM, Martin D, de Lonlay P, et al. J Inherit Metab Dis. 1999;22(4):488-502. 18. Shekhawat PS, Matern D, Strauss AW. Pediatr Res. 2005;57(5 Pt 2):78R-86R. 19. Vockley J, Burton B, Berry GT, et al. Mol Genet Metab. 2017;120(4):370-377. 20. Siddiq S, Wilson BJ, Graham ID, et al. Orphanet J Rare Dis. 2016;11(1):168.

Stay Informed

Sign up to receive the current disease education information in your inbox.